Abstract: Chronic pain is the central problem in a variety of urological diseases. Pain is an unpleasant sensory and emotional experience associated with either actual or potential tissue damage, or described in terms of such damage. The aim of this research was to update knowledge about the ultrastructural, clinical, psychological and therapeutic aspects of chronic pain in urological diseases, in particular in chronic pelvic syndrome. In this paper we have revisited the most significant and discussed articles published in the last twenty five years, with particular references on the 2008 European Guidelines, searching key words (chronic pelvic pain syndrome, chronic pelvic pain, chronic prostatitis, interstitial cystitis, prostatodynia, urological disease) and data with a high level of evidence. The articles that we have analyzed show that pain is characterized by an initial tissue injury that can lead to sensitization, which is a decrease in the intensity of the stimulus needed to elicit a response by the nerve, involving the peripheral and central nervous systems. The chronic pain state is characterized by loss of inhibitory interneurons, establishment of aberrant excitatory synaptic connections and long-term potentiation of response due to changes in sensitivity of nerve synapses. Stress and hormones might also play a role in central sensitization. Pain also has a cognitive and emotional component. It is very difficult to treat, given the complex nature of the response and the interaction of physiological aspects © Versita Warsaw and Springer-Verlag Berlin Heidelberg.
Introduction
Chronic Prostatitis Syndrome (CPS) is a common disease that has a very negative impact on the patient's quality of life. The classification proposed by the National Institutes of Health is widely adopted; it describes the disease as ''Chronic Prostatitis/Chronic Pelvic Pain Syndrome'' and includes four categories. Among these, Category III includes Chronic Inflammatory Prostatitis and Prostatodynia, which comprise the focus of the current article.
Symptoms from CPS are variable and nonspecific. Some authors [1, 2] have stated that pain, present for at least 3 months, is the most common and most typical of all symptoms. The pain is most frequently located in the perineum but other parts of the pelvic region can be affected, including penis, urethra, scrotum, testicles, and sometimes with irradiation to the lower back. Because the majority of patients with CPS fall into category III (chronic pelvic pain), pain should be, by definition, the most typical manifestation.
CPS and interstitial cystitis may share common pathogenetic mechanisms. Some symptoms of CPS, especially pelvic pain, may be indistinguishable from those of interstitial cystitis (IC) [3, 4] . The latter condition is more frequently seen in women than in men, which means that the possibility of IC in men is often disregarded and the diagnosis is missed, especially if non-bladder related symptoms are present [5] . Not only is the diagnosis of IC in general made much more frequently than it was 20 years ago, but also, according to Parson [6] , a recent survey has shown a femaleto-male ratio of 5:1, which is substantially lower than previously believed (10:1). That study has also shown that there was an overlap between men diagnosed with IC and those diagnosed with prostatitis, suggesting that both conditions may be part of the same disease process, probably consisting of a dysfunction of the lower urinary epithelium and potassium recycling [7] . Because the number of patients who report a history of prostatitis is higher than that of patients in whom the diagnosis of CPS is confirmed, it is possible that incorrect diagnoses of IC may account for the discrepancy.
Definition of "Pain" and "Chronic Pelvic
Pain"
The International Association for the Study of Pain (IASP) has proposed a working definition: "Pain is an unpleasant sensory and emotional experience associated with either actual or potential tissue damage, or described in terms of such damage" [8] . In terms of its origin, two different kinds of pain exist. The first is termed "nociceptive", because it is linked with noxious stimuli or physiological; it is associated with tissue damage or inflammation, so it is also called inflammatory pain. The second is termed "neuropathic" and results from a lesion to the peripheral or central nervous systems. Pain can also be divided into two other categories: "acute" and "chronic". "Acute" pain occurs after traumas, operations or lesions of a nerve, and it is often recurrent. In contrast to this, "chronic" pain occurs continuously for at least 3 months. It inhibits feelings, emotions, thinking and reactions. Social interactions and work are restricted to the extent that mobility and physiological functions are inhibited. Chronic pelvic pain, for instance, is non-malignant pain perceived in structures related to the pelvis in both men and women [9] . In the case of documented nociceptive pain that becomes chronic, the pain must have been continuous or recurrent for at least 6 months. If non-acute pain mechanisms are documented, then the pain may be regarded as chronic, irrespective of the time period. In all cases, there may be associated negative cognitive, behavioral, and social consequences.
Chronic Pelvic pain syndrome (CPPS) is the occurrence of persistent or recurrent episodic pelvic pain associated with symptoms suggestive of lower urinary tract, sexual, bowel, or gynaecological dysfunction. There is no proven infection or other obvious pathology (International Continence Society (ICS) 2002). Other  kinds of chronic pelvic pain are bladder pain, urethral  pain, penile pain, prostate pain, perineal pain, scrotal and testicular pain, and pelvic floor muscle pain [10] . There is currently no ideal classification for those conditions that may be considered under the chronic pain syndrome. The axes used above are based on the IASP classification [8] . Much of the terminology comes from the ICS classification of chronic pain [9, 10] with input from the ISSVD and the IASP special interest group, Pain of Urogenital Origin (PUGO) and Specialists in Pain International Network (SPIN). The major controversy within this area is that a pain may involve multiple sites, aetiologies and mechanisms.
Ultrastructural aspects of chronic pain
The nervous system provides information about the occurrence or threat of injury; the sensation of pain contributes to this function. The peripheral neural apparatus that responds to noxious stimuli provides a signal to alert the organism of potential injury. The protective mechanism operates as a result of the presence of a specific set of primary sensory neurones called "nociceptors." These highly specialized sensory fibres provide information to the central nervous system, not only about the environment, but also about the state of the organism itself.
"Nociceptors" are sub-classified according to three criteria: 1) unmyelinated (C-fiber) versus myelinated (A-fiber) parent nerve fiber; 2) Modalities of stimulation that evoke a response; and 3),, response characteristics. The nociceptive response relies on he interventions of numerous chemicals substances (bradykinin, prostaglandins, leukotrienes, serotonin, histamine, substance P, thromboxanes, platelet activating factor, protons, free radicals) and of cutaneous nerves (more than a fourfold higher number of small diameter A -and C-fibres than the larger, myelinated A -fibres). The nociceptors terminate in the dorsal horn of the spinal cord with the thinly myelinated A-delta ending in laminae I and V and the unmyelinated C-fibres in lamina II. These high-threshold sensory fibers activate a large number of second-order interneurones and projection neurones in the spinal cord. The activity generated by nociceptor input is transferred, after complex active processing in the dorsal horn, directly or via brainstem relay nuclei, to the thalamus and then onto the cortex, where the sensation of pain is generated. Numerous brain areas are also involved in the various components of pain; these include 1) a sensorydiscriminative component that refers to the capacity to analyse location, intensity and duration of the nociceptive stimulus; 2) a motivational component that gives rise to the unpleasant character of painful perception; 3) a cognitive and evaluative component involved in the phenomena of anticipation, attention, suggestion and past experiences; and 4) a behavioral component that refers to what the patient says and does (or does not say), meaning he is suffering.
Pain as a complex phenomenon in CP and in IC
Changes in the central and peripheral nervous system in response to or in anticipation of pain alter the organism's perception of the stimulus. People do not experience the level of pain after similar noxious stimuli.
In the nervous system, neurotransmitters, cytokines, and neuropeptides change character and concentration, genes are activated, and new axonal connections are made. Responses to stimuli might undergo long-term augmentation, and some neural activity leading to pain might occur spontaneously. Indeed, men with Chronic Pelvic Pain Syndrome (CPPS) have pain sensitization to heat and mechanical stimuli, meaning they experience stimuli in the pelvis more intensely than men without CPPS; men with pain who have a tendency to view adverse events as catastrophic are more likely to have more intense or a longer course for pain. So, prostatitis must be viewed as more than an organ-specific disease.
Pain is the central problem in men with CP/CPPS. The experience of pain and suffering necessarily involves the nervous system in producing or mediating these symptoms. Our understanding of the causes of CP/CPPS requires a working knowledge of how nerves respond to stimuli and the factors that influence a patient's interpretation of this stimulation. The initiating event is a noxious stimulus, such as from trauma, infection, or peripheral inflammation. Nociception then leads to its conscious perception (pain). The perceived pain is modulated by factors in the periphery, the spinal cord and the brain. The idea that the neurologic response is not static but able to be modified by feedback is a central idea of pain physiology, called the "gate theory". Pain can also be reported by the CNS in the absence of nociception and be spontaneously perceived, such as in phantom limb pain and pain after stroke.
Pain represents a human symptom requiring a multidisciplinary management team for effective treatment. The problem in patients with chronic visceral pain, such as CP/CPPS, is that the initial event (infection or trauma) sets up a pain experience that persists long after the initial stimulus is gone. Tissue injury can lead to sensitization, a decrease in the intensity of the stimulus needed to elicit a response by the nerve. This sensitization can occur in both the peripheral nervous system and CNS. Mechanisms underlying this development of the chronic pain state, independent of the initiating event, include changes in gene expression in the CNS, loss of inhibitory interneurons, establishment of aberrant excitatory synaptic connections and long-term potentiation of response due to changes in sensitivity of nerve synapses.
Stress might also play a role in central sensitization. Several neurotransmitters are responsible for central sensitization in chronic pain states. In animal models, there is an increase in staining for substance P, calcitonin gene-related polypeptide (CGRP), PACAP (pituitary adenylate cyclase activating protein), and other neurotropic factors, including nerve growth factor (NGF).
Hormones are involved in both the organization and activation of the CNS. For example, male rat pups castrated 1 day after birth display adult analgesic responses to morphine similar to those in adult females; conversely, female pups androgenized with testosterone exhibit responses similar to those in adult males. The periaqueductal gray (PAG) area, located near paininhibitory centers, is one brain area that is involved in the differential effects of organization by hormones; the PAG is also a site in the emotional motor system, a link between emotions and pain perception.
There are two types of pain: visceral and somatic. Nociception in internal organs, or visceral pain, differs from somatic pain in several respects. Visceral pain is diffuse and poorly localized; it is referred and not felt at the source because of an extensive arborization of sensory nerves in the spinal cord levels. Nociception is felt not just at one level of the spinal cord but at several levels at once. These areas are also receiving input from other viscera and somatic structures at the same time, leading to a mechanism for modulation of the painful area on other areas, and vice versa. The input from nociceptors is also multimodal; input can include, for example, both mechanical and thermal afferents at the same time.
Visceral pain can be produced by stimuli different than that necessary to produce somatic pain. Injury is not required for visceral pain: it can be induced by hollow organ dissension, traction on the mesentery, ischemia, and chemicals. Also, visceral pain is associated with emotional and autonomic responses not seen with somatic pain. There is also increased input from higher CNS centers that influence the spinal response to nociception. There can also be changes in the type of sensory fibers that mediate a pain response. Normal visceral sensation is carried by myelinated A delta fibers. However, with a noxious stimulus, previously silent unmyelinated C fibers can become activated and activated C fibers might fire more vigorously. C fibers, so called because they respond to capsaicin, contain many sensory neuropeptides, many of which are associated with somatic pain, such as substance P and CGRP.
Chronic pain is very difficult to treat, given the complex nature of the response and the interaction of the physiologic and subsequent psychosocial changes that occur and that can help to perpetuate the condition.
Cognition and Emotion in Pain Perception
Psychophysical studies [13] [14] [15] [16] have shown that pain perception is altered both by attention to the pain and the mood of the patient, but the nature of the modulation differs in individuals. The degree of attention to the pain alters primarily the perceived intensity of the pain, whereas mood alters primarily the unpleasantness associated with the pain. Human studies have shown that attention and distraction show modulation of pain evoked activity in the thalamus, the somato-sensory cortex, the anterior cingulate cortex (ACC), and the insular cortex. Other regions, including PAG, parts of the ACC, and orbital frontal cortex, have been shown to be activated when subjects are distracted from pain, suggesting that these regions might be involved in the modulatory circuitry related to attention. These basic psychophysical studies not only improve our understanding of pain modulation in conditions such as CP and IC but also point to potential therapeutic targets.
Depression and catastrophizing in Chronic Pain State
Depression often accompanies persistent pain, including chronic pelvic pain, and depression rates in pain patients are higher than those seen in the general population. Prospective studies (including studies in CP and IC) [17, 21] indicate that persistent pain increases the risk for depression, and also suggest that depression increases the risk for persistent pain. Further studies suggest that elevated rates of depression seen in chronic pelvic pain are related to the experience of pain, not the presence or absence of an organic cause [18] [19] [20] [21] .
Pelvic Pain Is Sexual Pain
Men with CP, when asked, have reported sexual problems of pain during or immediately after sexual intercourse (associated with ejaculation), decreased frequency of sexual activities, varying degrees of erectile dysfunction, and decreased libido. Recent studies [22] [23] [24] have shown that men with CP report less sexual pleasure and satisfaction. Sexual functioning as a predictor of poor quality of life and disability must be explored in future studies.
Treatment of chronic pelvic pain

Non-acidic antipyretic analgesics
Paracetamol is considered for treatment of mild pain [25] ( Table 1 ).
Acidic antipyretic analgesics
The classical NSAIDs, including salicylic acid, fall into this group. They are known to act on the cyclooxygenase (COX) enzyme ( Table 1) . The early NSAIDs tend to have little selectivity for COX2 over COX1, and are associated with more side effects than the newer COX2 selective inhibitors. However, the selective COX2 agents should not be prescribed for patients with increased risk of cardiovascular disease, including congestive cardiac failure [26, 27] .
For practical purposes the NSAIDs may be divided into the following categories: 1) on-selective, low potency (e.g. salicylic acid, ibuprofen, mefenamic acid); 2) nonselective, high potency (e.g. ketoprofen, diclofenac, ketorolac); and 3) COX2 selective drugs (e.g. celecoxib, etoricoxib).
Non-selective, low potency NSAIDs should be used in the first instance. They are most likely to be of help if there is an inflammatory component to the pain [28] . More potent NSAIDs should be reserved for those conditions in which the low potency drugs have been tried and have failed to produce significant benefit. 
Opioids
The opioids can be used only when all other reasonable treatments have been tried and failed. If there is a history or a suspicion of drug abuse, the decision to start longterm opioid therapy should be made by an appropriately trained specialist in consultation with another physician (preferably the patient's family doctor). The patient should undergo a trial of intravenous [29] or oral opioids [30] . The patient may be requested to attend a psychiatric/psychology review, and the failure to comply with the above may result in the patient being referred to a drug dependency agency and the use of therapeutic, analgesic opioids being stopped [31, 32] ( Table 1 ).
Opioid-like agents
Tramadol produces analgesia by two mechanisms: an opioid effect and an enhancement of serotoninergic and adrenergic pathways [33, 34] . It has fewer of the typical opioid side effects (notably, less respiratory depression, less constipation, and less addiction potential) ( Table 1 ).
Neuropathic analgesics
Tricyclic antidepressants. There is very little evidence available from human trials [35, 36] (Table 1) . Serotonin reuptake inhibitors. Fluoxetine can increase plasma levels of amitriptyline and induce toxicity, and therefore care must be exercised if the drugs are combined [37] .
Anticonvulsants have been used in the management of pain for many years. Among them, carbamazepine has significant side effects. Gabapentin has recently been introduced for pain management, and is said to have fewer side effects. In some countries it is now licensed for use against chronic neuropathic pain [38, 39] .
N-methyl-D-aspartate (NMDA) antagonists. The NMDA receptor channel complex is known to be an important channel for the development and maintenance of chronic pain. It is felt to be particularly important when there is evidence of central sensitization and opioid tolerance [40] .
Ketamine is thought to act primarily at the NMDA receptor, although it may also have actions at sodium channels, as well as opioid (kappa and mu) receptors [41] .
Ketamine has been shown to reduce central sensitization and wind-up in both human and animal models of neuropathic pain [42, 43] . It should only be used by an experienced practitioner trained in its use.
Sodium channel blockade. Neuropathic changes are thought to play a role in chronic pelvic pain. These may be associated with a reduction of some sodium channels and the development of novel sodium channels, and also with a change in the distribution of these channels. Nociceptive pain may be reduced with intravenous lidocaine, but only with high doses [44, 45] .
Nerve Blocks
Peripheral nerve blocks, such as ilioinguinal/ iliohypogastric/genitofemoral, may be useful in neuropathic pain associated with nerve damage. Blocks around the spermatic cord may be useful diagnostically prior to testicular denervation. Lumbar (L1) sympathetic blocks may be helpful in the management of testicular pain and other pelvic conditions with afferents passing to the L1 level. Pudendal nerve blocks may be useful in the management of pudendal nerve injury and pelvic floor muscle spasm [46, 47] .
Transcutaneous electrical nerve stimulation (TENS)
The rationale for using surface electrical nerve stimulation to relieve pain is the stimulation of myelinated afferents, and thereby, the activation of segmental inhibitory circuits. TENS may directly elicit reflex effects and influence autonomous functions. Kim [48] showed the clinical efficacy of intermittent percutaneous posterior tibial nerve stimulation (PTNS) in 15 patients (10 women and 5 men, mean age 60.0 years) with chronic pelvic pain (CPP). The patients had 12 weekly outpatient treatment sessions, each lasting 30 min. After 12 weeks of PTNS, 9 (60%) and 3 patients (30%) had an improvement of > 50% and 25-50% in the Visual Analogue Scale (VAS) score for pain, respectively. Six patients (40%) ended up with a mean VAS < 3. Mean VAS for pain changed from 8.1 +/-0.2 at baseline to 4.1 +/-0.6 after 12 weeks of treatment (p < 0.01). Mean VAS for urgency changed from 4.5 +/-1.0 at baseline to 2.7 +/-0.7 after 12 weeks of treatment (p < 0.05). However, there was neither statistically significant improvement in the International Prostate Symptom Score, nor statistically significant difference in the number of voids and bladder volumes. In another study, 33 persons with classic IC, and 27 with non-ulcer disease, were treated by suprapubic TENS [49] . Follow-up ranged from 9 months to 17 years. Patients who responded reported more marked effects on bladder pain than on micturition frequency. Nine patients with classic IC had remission of symptoms after treatment of longer than 1 year. Another 9 patients experienced adequate pain relief with daily treatments, but could not stop TENS without recurrence of symptoms. Nine patients had only a moderate palliation and abandoned the treatment. The remaining six patients reported no symptom improvement at all. Thus, 54% of the patients with classic IC were helped by the treatment.
The outcome of TENS was less favorable in nonulcer IC. Of 27 patients, 4 reported remission of pain and urinary frequency and 3 adequate pain palliation, but persistent voiding frequency during continuing TENS. Five had moderate effect and 15 had no pain relief. Thus, only 26% of the patients with non-ulcer IC benefited from the treatment.
The beneficial effect of TENS on classic IC clearly exceeds the level of the placebo effect observed in drug studies of IC (54% versus 13-20%) [50, 51] .
Sacral neuromodulation
Sacral neuromodulation has been shown to have benefits in patients with refractory motor urge incontinence [52, 53] , urinary retention, and chronic pelvic pain [54, 55] . Neuropathic pain and complex regional pain syndromes may also be treated successfully with neurostimulation applied to dorsal columns and peripheral nerves [56] . Neurostimulation of S3 or S4 sacral nerves using a transforamenal approach is emerging as a viable option for patients with refractory urinary voiding disorders. Recently, sacral neuromodulation has also been investigated in IC. In an initial report on six patients [57] , percutaneous neurostimulation significantly improved frequency, pain and urgency towards normal values, while urinary markers for IC were normalized. Maher et al. [58] reported a favorable response with significant improvement in pelvic pain, daytime frequency, nocturia, urgency and voided volume in 15 women with IC.
Because pelvic pain syndromes are viewed as a manifestation of disturbed neural function, patients with refractory pelvic floor dysfunction and pelvic pain have been treated with sacral neuromodulation and benefit has been reported [59] . Sacral neuromodulation for chronic pelvic pain is the beneficiary of promising data from pilot studies, such that prospective, placebocontrolled studies are justified.
Psychosocial Therapy
Certainly, randomized controlled trials have supported the efficacies of these cognitive-behavioral therapies for a variety of chronic pain problems, including low back pain and arthritis [60, 61] . However, research has not examined the effectiveness of these therapies for CP (or IC). Scientific data can be used to develop evidencebased psychosocial treatment protocols that can and should be assessed in prospective trials on both CP and IC.
Conclusions
Many factors, such as genetic makeup, personality, attitudes, social/cultural environment, coping strategies, perceptions of control, emotions, and behavioral disturbances all interact with chronic pain to determine the individual patient's adaptation to persistent pain. The CP research community must explore these dimensions in patients suffering from the disease in order to provide solid data for the development of individualized evidence-based bio-psycho-social treatment protocols. The traditional biomedical models must continue to be pursued by the scientific community because they hold the key to the initiation of the condition in susceptible individuals. For any treatment to be successful (or curative), the factors that initiate the inflammatory and neuropathic state or continue to create continued inflammation and/or peripheral nerve stimulation must be dealt with. However, in patients with long-standing pain, the psychosocial therapeutic model likely holds the key to long term amelioration of pain (or at least increased tolerance of pain), decreased disability, and improved quality of life in patients suffering from CPPS.
